JP2018524987A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524987A5
JP2018524987A5 JP2018501339A JP2018501339A JP2018524987A5 JP 2018524987 A5 JP2018524987 A5 JP 2018524987A5 JP 2018501339 A JP2018501339 A JP 2018501339A JP 2018501339 A JP2018501339 A JP 2018501339A JP 2018524987 A5 JP2018524987 A5 JP 2018524987A5
Authority
JP
Japan
Prior art keywords
cell
cells
tcm
phenotype
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018501339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524987A (ja
JP7057748B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2016/050775 external-priority patent/WO2017009853A1/en
Publication of JP2018524987A publication Critical patent/JP2018524987A/ja
Publication of JP2018524987A5 publication Critical patent/JP2018524987A5/ja
Application granted granted Critical
Publication of JP7057748B2 publication Critical patent/JP7057748B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018501339A 2015-07-16 2016-07-14 遺伝子改変された抗第三者中枢性メモリーt細胞および免疫療法におけるその使用 Active JP7057748B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562193229P 2015-07-16 2015-07-16
US201562193207P 2015-07-16 2015-07-16
US62/193,207 2015-07-16
US62/193,229 2015-07-16
PCT/IL2016/050775 WO2017009853A1 (en) 2015-07-16 2016-07-14 Genetically modified anti-third party central memory t cells and use of same in immunotherapy

Publications (3)

Publication Number Publication Date
JP2018524987A JP2018524987A (ja) 2018-09-06
JP2018524987A5 true JP2018524987A5 (enExample) 2019-08-29
JP7057748B2 JP7057748B2 (ja) 2022-04-20

Family

ID=56555512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018501339A Active JP7057748B2 (ja) 2015-07-16 2016-07-14 遺伝子改変された抗第三者中枢性メモリーt細胞および免疫療法におけるその使用

Country Status (11)

Country Link
US (4) US10933124B2 (enExample)
EP (2) EP3322425B1 (enExample)
JP (1) JP7057748B2 (enExample)
CN (3) CN108025026A (enExample)
AU (1) AU2016291825B2 (enExample)
CA (1) CA2991690A1 (enExample)
DK (1) DK3322425T3 (enExample)
ES (2) ES2963038T3 (enExample)
IL (1) IL256916B2 (enExample)
PL (2) PL3322424T3 (enExample)
WO (2) WO2017009852A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2506311C2 (ru) 2008-10-30 2014-02-10 Йеда Рисёрч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
KR102073901B1 (ko) 2011-09-08 2020-02-05 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 항 제3자 중심 기억 t 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도
CN106687125B (zh) * 2014-03-12 2021-12-14 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
DK3322425T3 (da) 2015-07-16 2023-06-12 Yeda Res & Dev Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
US10961504B2 (en) 2016-06-27 2021-03-30 Yeda Research And Development Co. Ltd. Veto cells generated from memory T cells
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
WO2018134824A1 (en) 2017-01-18 2018-07-26 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
CN107573419A (zh) * 2017-01-24 2018-01-12 深圳市体内生物医药科技有限公司 一种增强t细胞抗肿瘤活性的核酸分子
CN107254489B (zh) * 2017-06-19 2021-06-18 河南省华隆生物技术有限公司 一种检测嵌合抗原受体或基因修饰的t细胞受体表达的方法和应用
JP7570231B2 (ja) * 2018-02-02 2024-10-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体を発現する改変された単球/マクロファージ/樹状細胞、ならびにタンパク質凝集物に関連する疾患および障害における使用
WO2019222762A1 (en) * 2018-05-18 2019-11-21 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
EP4458419A3 (en) * 2018-09-10 2025-01-08 Atara Biotherapeutics, Inc. Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
BR112021021349A2 (pt) 2019-04-26 2022-02-01 Allogene Therapeutics Inc Métodos de fabricação de células car t alogênicas
CN110358734B (zh) 2019-06-13 2020-08-25 首都医科大学宣武医院 以Tcm为主要效应成分的CAR-T制备方法及其应用
CA3149379A1 (en) * 2019-08-06 2021-02-11 Yeda Research And Development Co. Ltd. Anti-viral central memory cd8+ veto cells in haploidentical stem cell transplantation
CN110628717B (zh) * 2019-10-28 2020-10-30 上海科医联创生物科技有限公司 一种浸润性t细胞的培养方法
AU2020379319A1 (en) * 2019-11-05 2022-06-23 Yeda Research And Development Co. Ltd. Use of veto cells in treatment of T cell mediated autoimmune diseases
MX2022005418A (es) * 2019-11-05 2022-08-15 Yeda Res & Dev Uso de celulas de veto para el tratamiento de la enfermedad de celulas falciformes.
AU2021228701A1 (en) * 2020-02-28 2022-09-15 KSQ Therapeutics, Inc. Methods for activation and expansion of tumor infiltrating lymphocytes
CA3184807A1 (en) 2020-06-04 2021-12-09 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
JP2023537133A (ja) * 2020-08-11 2023-08-30 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ベトcar-t細胞
US20240001142A1 (en) * 2020-10-07 2024-01-04 Board Of Regents, The University Of Texas System Induction by low dose radiation of cancer cell targets for cell-based or small molecule therapy

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
EP0668013B1 (en) 1994-02-22 2005-04-20 Nippon Telegraph And Telephone Corporation Freeze-dried blood cells, stem cells and platelets and manufacturing method for the same
US5955257A (en) 1997-10-21 1999-09-21 Regents Of The University Of Minnesota Infusible grade short-term cell storage medium for mononuclear cells
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
US6447765B1 (en) 1998-03-03 2002-09-10 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
WO2000039294A1 (en) 1998-12-24 2000-07-06 Novartis Ag Porcine cells incapable of expressing cd40 antigen, for xenotransplantation
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6544506B2 (en) 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
AU5340001A (en) 2000-04-11 2001-10-23 Univ Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
JP2004517806A (ja) 2000-07-03 2004-06-17 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ctla4分子を使用するリウマチ疾患の処置方法
AU2002221013A1 (en) 2000-11-30 2002-06-11 Yeda Research And Development Co..Ltd. Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
JP4837880B2 (ja) 2001-05-23 2011-12-14 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ctla4突然変異体分子を使って同種異系島移植片を保護する方法
US20030147859A1 (en) 2001-06-18 2003-08-07 Yair Reisner Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance
US20040136972A1 (en) 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US7504099B2 (en) 2001-12-27 2009-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of inducing or enhancing connective tissue repair
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030215942A1 (en) 2002-02-14 2003-11-20 Stemcyte, Inc. Undesignated allogeneic stem cell bank
AU2003228768B2 (en) 2002-05-22 2009-02-05 The Cleveland Clinic Foundation Induction and maintenance of tolerance to composite tissue allografts
IL165425A0 (en) 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
NZ573652A (en) 2003-08-04 2009-11-27 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
WO2005067956A2 (en) 2004-01-15 2005-07-28 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection
WO2005092380A2 (en) 2004-03-26 2005-10-06 Pfizer Products Inc Uses of anti-ctla-4 antibodies
WO2006041763A1 (en) 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
WO2006040763A2 (en) 2004-10-12 2006-04-20 Technion Research & Development Foundation Ltd. Isolated primate embryonic cells and methods of generating and using same
DK1814580T3 (en) 2004-11-24 2016-12-12 Hutchinson Fred Cancer Res Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
MX2007012222A (es) 2005-04-06 2007-12-06 Bristol Myers Squibb Co Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.
WO2007023491A2 (en) 2005-08-24 2007-03-01 Yeda Research And Development Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US8361473B2 (en) 2007-03-29 2013-01-29 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
WO2009053109A1 (en) 2007-10-24 2009-04-30 Anne Letsch Antigen-specific t-cell preparations from bone marrow
WO2009125395A1 (en) 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti influenza antibodies and uses thereof
US8747855B2 (en) 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
US8200915B2 (en) 2008-08-22 2012-06-12 Cadence Design Systems, Inc. Management of very large streaming data sets for efficient writes and reads to and from persistent storage
RU2506311C2 (ru) * 2008-10-30 2014-02-10 Йеда Рисёрч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
EP2494038B1 (en) 2009-10-27 2019-06-26 Immunicum AB Method for proliferation of antigen-specific t cells
ES2686424T5 (es) * 2010-05-04 2023-03-27 Yeda Res & Dev Inmunoterapia con células alogénicas redireccionadas
CA2805478A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
CN105907713A (zh) 2010-09-08 2016-08-31 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
US20130183322A1 (en) 2010-09-08 2013-07-18 Yeda Research And Development Co., Ltd. Immunosuppressive drug combination for a stable and long term engraftment
JP6203705B2 (ja) 2011-03-23 2017-09-27 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための方法および組成物
AU2012249540B2 (en) * 2011-04-29 2017-07-13 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
KR102073901B1 (ko) * 2011-09-08 2020-02-05 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 항 제3자 중심 기억 t 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도
KR20140102730A (ko) 2011-12-08 2014-08-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 포유류 태아 폐 세포와 이를 치료용으로 사용하는 방법
CN104470542A (zh) 2011-12-22 2015-03-25 耶达研究及发展有限公司 用于稳定和长期植入的联合疗法
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
PH12019550223A1 (en) * 2012-08-20 2024-02-19 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
WO2014039044A1 (en) * 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
JP6401704B2 (ja) * 2012-10-10 2018-10-10 サンガモ セラピューティクス, インコーポレイテッド T細胞を修飾する化合物およびその使用
US9499855B2 (en) * 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
CN105518018B (zh) 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CN112795594B (zh) * 2013-05-14 2025-09-19 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
US10131876B2 (en) * 2014-04-24 2018-11-20 Miltenyi Biotec Gmbh Method for automated generation of genetically modified T cells
WO2015184099A1 (en) 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof
CA2965347C (en) 2014-10-27 2023-03-14 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
BR112017008693A2 (pt) 2014-10-31 2018-02-27 The Trustees Of The University Of Pennsylvania célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição.
IL316196A (en) 2015-05-28 2024-12-01 Us Health Methods of conditioning patients for t cell therapy
DK3322425T3 (da) * 2015-07-16 2023-06-12 Yeda Res & Dev Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
MX2018007295A (es) 2016-01-11 2019-03-28 Armo Biosciences Inc Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
CN109475581A (zh) 2016-05-22 2019-03-15 耶达研究及发展有限公司 为了移植及诱导耐受性而使用肺细胞的方法
US10961504B2 (en) 2016-06-27 2021-03-30 Yeda Research And Development Co. Ltd. Veto cells generated from memory T cells
WO2018134824A1 (en) 2017-01-18 2018-07-26 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
US10751368B2 (en) * 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment

Similar Documents

Publication Publication Date Title
JP2018524987A5 (enExample)
JP7317793B2 (ja) 改変γδT細胞
JP2019536461A5 (enExample)
Bézie et al. Advances on CD8+ Treg cells and their potential in transplantation
JP2019527041A5 (enExample)
Choreno Parra et al. Memory of natural killer cells: a new chance against Mycobacterium tuberculosis?
JP2017512484A5 (enExample)
JP2019518460A5 (enExample)
JP2017535292A5 (enExample)
RU2017111298A (ru) Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2
Fan et al. Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood
Sagoo et al. Regulatory T cells as therapeutic cells
Ma et al. CAR-NK cells effectively target SARS-CoV-2-spike-expressing cell lines in vitro
JP2014087372A5 (enExample)
RU2013147157A (ru) Способ и композиции для клеточной иммунотерапии
JP2021505604A5 (enExample)
MA40253A (fr) Cellules modifiées pour thérapie cellulaire adoptive
RU2018113510A (ru) Химерные рецепторы антигена, нацеленные на psca
Merker et al. Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children
RU2018140056A (ru) Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена
JP2024086827A5 (enExample)
Tuomela et al. Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes
EP4458419A3 (en) Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
Slepicka et al. Harnessing mechanisms of immune tolerance to improve outcomes in solid organ transplantation: a review
Seok et al. Roles of virtual memory T cells in diseases